Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Journal of Transfusion Medicine
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2020

open access

Vol 11, No 3 (2018)
Research paper
Published online: 2019-01-15
View PDF (polish) Download PDF file
Get Citation

Evaluation of the Roche cobas DPX Test performed on the cobas® 6800 system and cobas p 680 instrument for parvovirus B19 DNA and HAV RNA detection in blood donations

Aneta Kopacz, Dorota Kubicka-Russel, Grzegorz Liszewski, Paulina Zwolińska, Ewa Sulkowska, Aleksandra Kalińska, Jolanta Korzeniowska, Magdalena Łętowska, Piotr Grabarczyk
Journal of Transfusion Medicine 2018;11(3):91-99.

open access

Vol 11, No 3 (2018)
ORIGINAL PAPERS
Published online: 2019-01-15

Abstract

Introduction The cobas DPX test for use on the cobas 6800 system, is real-time PCR test for the identification and quantitation of human parvovirus B19 (B19V) DNA and the detection of hepatitis A virus (HAV) RNA in human plasma. Optional component to the cobas 6800 system is the cobas p 680 instrument that creates pools from individual samples. Aim To evaluate the performance of cobas® DPX test and to demonstrate its ability to detect HAV and polymorphic forms of B19V during plasma testing. Sensitivity, correct identification of reactive donations and risk of false positive results was estimated. Material and method The analytical sensitivity of cobas® DPX test was assessed by testing dilutions of the WHO B19V Genotype 1-3 Reference Panels (09/110) and IS WHO RNA HAV (00/562) dilution panel. Six dilutions of each B19 panel were tested ranging from 31.6 IU/mL to 0.1 IU /mL of genotype 1, 2, 3 and six dilutions of RNA HAV panel ranging from 10-0,03 IU/ml (24 replicates/dilution). Detection and identification of reactive donations tested in minipools were evaluated by testing 767 negative and 1 high DNA B19V reactive donations in 8 pools. Results The 95% limits of detection [LOD] (95% confidence range) of the cobas® DPX test for DNA B19V were respectively: genotype 1 - 8.70 IU/mL (4.92-21.69), genotype 2 - 37.80 IU/ml (22.24 – 93.65), genotype 3 - 29.84 IU/ml (19.04-65.60) and for RNA HAV were: 0.82 IU/ml (0.49 -1.96). Results of the cobas® DPX test from samples analyzed in minipools were 100% concordant with the expected results. No false reactive or invalid results was observed during donation screening. Conclusion The cobas® DPX test on the cobas 6800 system allows to identify donations infected with HAV and genotypes 1-3 of B19V that could result contamination of plasma production pools with HAV and B19V beyond acceptable level (>104 IU/mL, according to recommendations). There was no significant risk of false results during evaluation procedure.

Abstract

Introduction The cobas DPX test for use on the cobas 6800 system, is real-time PCR test for the identification and quantitation of human parvovirus B19 (B19V) DNA and the detection of hepatitis A virus (HAV) RNA in human plasma. Optional component to the cobas 6800 system is the cobas p 680 instrument that creates pools from individual samples. Aim To evaluate the performance of cobas® DPX test and to demonstrate its ability to detect HAV and polymorphic forms of B19V during plasma testing. Sensitivity, correct identification of reactive donations and risk of false positive results was estimated. Material and method The analytical sensitivity of cobas® DPX test was assessed by testing dilutions of the WHO B19V Genotype 1-3 Reference Panels (09/110) and IS WHO RNA HAV (00/562) dilution panel. Six dilutions of each B19 panel were tested ranging from 31.6 IU/mL to 0.1 IU /mL of genotype 1, 2, 3 and six dilutions of RNA HAV panel ranging from 10-0,03 IU/ml (24 replicates/dilution). Detection and identification of reactive donations tested in minipools were evaluated by testing 767 negative and 1 high DNA B19V reactive donations in 8 pools. Results The 95% limits of detection [LOD] (95% confidence range) of the cobas® DPX test for DNA B19V were respectively: genotype 1 - 8.70 IU/mL (4.92-21.69), genotype 2 - 37.80 IU/ml (22.24 – 93.65), genotype 3 - 29.84 IU/ml (19.04-65.60) and for RNA HAV were: 0.82 IU/ml (0.49 -1.96). Results of the cobas® DPX test from samples analyzed in minipools were 100% concordant with the expected results. No false reactive or invalid results was observed during donation screening. Conclusion The cobas® DPX test on the cobas 6800 system allows to identify donations infected with HAV and genotypes 1-3 of B19V that could result contamination of plasma production pools with HAV and B19V beyond acceptable level (>104 IU/mL, according to recommendations). There was no significant risk of false results during evaluation procedure.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

DNA B19V, parvowirus B19, RNA HAV, hepatitis A, blood donation screening

About this article
Title

Evaluation of the Roche cobas DPX Test performed on the cobas® 6800 system and cobas p 680 instrument for parvovirus B19 DNA and HAV RNA detection in blood donations

Journal

Journal of Transfusion Medicine

Issue

Vol 11, No 3 (2018)

Article type

Research paper

Pages

91-99

Published online

2019-01-15

Bibliographic record

Journal of Transfusion Medicine 2018;11(3):91-99.

Keywords

DNA B19V
parvowirus B19
RNA HAV
hepatitis A
blood donation screening

Authors

Aneta Kopacz
Dorota Kubicka-Russel
Grzegorz Liszewski
Paulina Zwolińska
Ewa Sulkowska
Aleksandra Kalińska
Jolanta Korzeniowska
Magdalena Łętowska
Piotr Grabarczyk

References (24)
  1. Qiu J, Söderlund-Venermo M, Young NS. Human Parvoviruses. Clin Microbiol Rev. 2017; 30(1): 43–113.
    CrossRefPubMed
  2. Siennicka J, Stefanoff P, Trzcinska A, et al. ąd serologiczny w kierunku zakażenia parwowirusem B19 w Polsce. Przegl Epidemiol. 2006; 60: 571–580.
  3. Grabarczyk P, Kalińska A, Kara M, et al. Identification and characterization of acute infection with parvovirus B19 genotype 2 in immunocompromised patients in Poland. J Med Virol. 2011; 83(1): 142–149.
    CrossRefPubMed
  4. Koppelman MH, Rood IGH, Fryer JF, et al. Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays. Vox Sang. 2007; 93(3): 208–215.
    CrossRefPubMed
  5. Baylis SA, Fryer JF, Grabarczyk P. Effects of probe binding mutations in an assay designed to detect parvovirus B19: implications for the quantitation of different virus genotypes. J Virol Methods. 2007; 139(1): 97–99.
    CrossRefPubMed
  6. Baylis SA, Shah N, Minor PD. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods. 2004; 121(1): 7–16.
    CrossRefPubMed
  7. Baylis SA, Buchheit KH. A proficiency testing study to evaluate laboratory performance for the detection of different genotypes of parvovirus B19. Vox Sang. 2009; 97(1): 13–20.
    CrossRefPubMed
  8. Grabarczyk P, Kalińska A, Sulkowska E, et al. False negative results in high viremia parvovirus B19-samples tested with real-time PCR. Pol J Microbiol. 2010; 59(2): 129–132.
    PubMed
  9. Yee TT, Cohen BJ, Pasi KJ, et al. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol. 1996; 93(2): 457–459.
    PubMed
  10. Blümel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 2002; 42(11): 1473–1481.
    PubMed
  11. Wu Cg, Mason B, Jong J, et al. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion. 2005; 45(6): 1003–1010.
    CrossRefPubMed
  12. Obwieszczenie Ministra Zdrowia z dnia 9 czerwca 2017 r. w sprawie wymagań dobrej praktyki pobierania krwi i jej składników, badania, preparatyki, przechowywania, wydawania i transportu dla jednostek organizacyjnych publicznej służby krwi (Dz. Urz. Ministra Zdrowia z 2017 r. , poz. ; 63).
  13. The European Pharmacopoeia (Ph. Eur. ), EDQM. ; 2017.
  14. Kalińska A, Kubicka-Russel D, Sulkowska E, et al. Polska Grupa ds. Badań Czynników Zakaźnych u Dawców Krwi w Centrach Krwiodawstwa i Krwiolecznictwa. Epidemiologia i przebieg zakażenia parwowirusem B19 u dawców krwi w Polsce w latach 2010–2017. XXVII Zjazd Polskiego Towarzystwa Hematologów i Transfuzjologów, 21–23 września 2017 r., Warszawa. Acta Haematologica Polonica. ; 2017(supl. 1): s189.
  15. Janaszek-Seydlitz W, Bucholc B, Wiatrzyk A. Poziom przeciwciał przeciwko wirusowemu zapaleniu wątroby typu A u osób z terenu Warszawy. Przegl Epidemiol. 2007; 61: 675–682.
  16. Wojewódzka Stacja Sanitarno-Epidemiologiczna w Poznaniu. Liczba zachorowań i zapadalność na wirusowe zapalenie wątroby typu A w Wielkopolsce i Polsce w latach 2009–2016 (tabela), http://www.wsse-poznan.pl.
  17. Zakład Epidemiologii NIZP-PZH. Zachorowania na wybrane choroby zakaźne w Polsce od 1 stycznia do 31 grudnia 2017 r. oraz w porównywalnym okresie 2016 r., http://wwwold.pzh.gov.pl/oldpage/epimeld/2017/INF_17_12B.pdf.
  18. Brojer E., Grabarczyk P. Czynniki zakaźne istotne w transfuzjologii. W: Brojer E., Kopacz A., Grabarczyk P. Wirus zapalenia wątroby typu A (HAV). Fundacja Pro Pharmacia Futura, Warszawa 2015: 61.
  19. da Silva SG, Leon LA, Alves G, et al. A Rare Case of Transfusion Transmission of Hepatitis A Virus to Two Patients with Haematological Disease. Transfus Med Hemother. 2016; 43(2): 137–141.
    CrossRefPubMed
  20. Gowland P, Fontana S, Niederhauser C, et al. Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus. Transfusion. 2004; 44(11): 1555–1561.
    CrossRefPubMed
  21. Korzeniowska J, Radwan-Wieczorek H, Kopacz A, et al. Charakterystyka testu ROCHE COBAS® TAQSCREEN DPX przeznaczonego do wykrywania parwowirusa B19V (B19V) u dawców krwi. Acta Haematologica Polonica. 2013; 44: 119–120.
    CrossRef
  22. Grabarczyk P, Kopacz A, Liszewski G, et al. Evaluation of the Roche Cobas Taqscreen DPX test for parvovirus B19 DNA genotypes detection in blood donors. Vox Sang. 2013; 105: 172.
  23. WHO Reference Reagent, 1st WHO International Reference Panel for Parvovirus B19, Genotypes for NAT based assays, NIBSC code:09/110, Instructions for use (version 1.0, Dated 10/03/2010).
  24. Lelie N, van Dr. Stability of native, lyophilised and inactivated HBV, HCV and HIV-1 plasma standards Vox. Sang. 2018; 113(Suppl. 1): 406.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl